Skip to content
Article Rich – Lifestyle
Author:
Upstream Bio
Upstream Bio Reports Third Quarter 2026 Financial Results and Highlights Continued Progress
November 10, 2026
Verekitug Phase 2 Trial Shows 56% Asthma Exacerbation Reduction
September 8, 2026
Upstream Bio Announces Pivotal Phase 3 Development Plans for Verekitug in Both Severe Asthma and CRSwNP
September 1, 2026
Upstream Bio Reports Second Quarter 2026 Financial Results and Highlights Continued Progress
August 11, 2026
Upstream Bio Presents New Responder Analyses Demonstrating Clinically Meaningful Improvements in CRSwNP in Significant Majority of Participants Treated with Verekitug in the Phase 2 VIBRANT Trial at EAACI 2026
June 14, 2026
Upstream Bio to Showcase Additional Efficacy Data from the Phase 2 VIBRANT Trial of Verekitug in CRSwNP in Oral Session at EAACI 2026
June 8, 2026
Upstream Bio to Present at the Goldman Sachs 47th Annual Global Healthcare Conference
June 3, 2026
Upstream Bio Presents New Data from Phase 2 VIBRANT Trial of Verekitug Demonstrating Improvement in Asthma Symptom Control in Participants with CRSwNP and Comorbid Asthma at the ATS 2026 International Conference
May 21, 2026